Last reviewed · How we verify
Sufentanil Sublingual Tablet System
Sufentanil Sublingual Tablet System is a Opioid analgesic Small molecule drug developed by Hospital Central do Funchal. It is currently FDA-approved for Acute pain management in opioid-tolerant patients, Breakthrough pain in opioid-tolerant cancer patients. Also known as: zalviso.
Sufentanil is a potent opioid agonist that binds to mu-opioid receptors in the central nervous system to produce analgesia and sedation.
The Sufentanil Sublingual Tablet System is a small molecule that acts as a mu opioid receptor agonist, classified as an agonist. It is used to treat conditions such as analgesia, postoperative pain, moderate-to-severe acute pain, and postoperative pain.
At a glance
| Generic name | Sufentanil Sublingual Tablet System |
|---|---|
| Also known as | zalviso |
| Sponsor | Hospital Central do Funchal |
| Drug class | Opioid analgesic |
| Target | Mu-opioid receptor (μ-OR) |
| Modality | Small molecule |
| Therapeutic area | Pain Management |
| Phase | FDA-approved |
Mechanism of action
Sufentanil activates mu-opioid receptors throughout the brain and spinal cord, inhibiting pain signal transmission and producing rapid onset analgesia. The sublingual tablet system allows for quick absorption through the oral mucosa, providing faster pain relief compared to oral formulations. It is approximately 5-10 times more potent than fentanyl.
Approved indications
- Acute pain management in opioid-tolerant patients
- Breakthrough pain in opioid-tolerant cancer patients
Common side effects
- Respiratory depression
- Dizziness
- Nausea
- Constipation
- Sedation
- Hypotension
Key clinical trials
- Safety and Efficacy of Patient Controlled Analgesia Using the Sublingual Sufentanil Tablet System (SSTS) in a Fast Track Rehabilitation Program After Total Knee Arthroplasty (PHASE4)
- Morphine vs Sufentanil PCA: Same Same or Different? (PHASE4)
- Sufentanil Sublingual Tablet System for Postoperative Pain Management After Total Knee Arthroplasty (NA)
- Sublingual Sufentanil Tablet System (SSTS) Versus Intravenous Patient Controlled Analgesia After Back Surgery. (NA)
- Acute Post-operative Pain in Colon Resections (NA)
- Study to Evaluate the Overall Performance of the Zalviso System™ (Sufentanil Sublingual Tablet System) 15 mcg (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sufentanil Sublingual Tablet System CI brief — competitive landscape report
- Sufentanil Sublingual Tablet System updates RSS · CI watch RSS
- Hospital Central do Funchal portfolio CI
Frequently asked questions about Sufentanil Sublingual Tablet System
What is Sufentanil Sublingual Tablet System?
How does Sufentanil Sublingual Tablet System work?
What is Sufentanil Sublingual Tablet System used for?
Who makes Sufentanil Sublingual Tablet System?
Is Sufentanil Sublingual Tablet System also known as anything else?
What drug class is Sufentanil Sublingual Tablet System in?
What development phase is Sufentanil Sublingual Tablet System in?
What are the side effects of Sufentanil Sublingual Tablet System?
What does Sufentanil Sublingual Tablet System target?
Related
- Drug class: All Opioid analgesic drugs
- Target: All drugs targeting Mu-opioid receptor (μ-OR)
- Manufacturer: Hospital Central do Funchal — full pipeline
- Therapeutic area: All drugs in Pain Management
- Indication: Drugs for Acute pain management in opioid-tolerant patients
- Indication: Drugs for Breakthrough pain in opioid-tolerant cancer patients
- Also known as: zalviso
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing